Onselex has developed and scaled ONX-1006, a novel nanomedicine that encapsulates paclitaxel in a proprietary nano-delivery platform. ONX-1006 is designed to selectively deliver chemotherapy to tumor cells, trigger apoptosis, and reduce systemic toxicity. In extensive preclinical studies, it demonstrated strong anti-tumor efficacy and a favorable safety profile, with the potential to significantly improve pancreatic cancer outcomes.